BUZZ-Repligen jumps on strong annual forecast and quarterly results beat

Life sciences firm Repligen's RGEN.O shares rise 8.9% to $164.1

Stock set for best day since July 2024 if gains hold

Co forecasts 2025 annual revenue in the range of $685 mln to $710 mln, above Wall Street estimates of $693.48 mln as per data compiled by LSEG

Co expects to earn between $1.67/share and $1.76/share for 2025 vs analysts' est of 1.67/share

Co reports Q4 profit of 44 cents/share vs analysts' est of 41 cents/share

Co posts Q4 revenue of $168 mln, beating analysts' estimates of $167.7 mln driven by more orders in its filtration and analytics unit

Stock has fallen 22% in the last 12 months